CH642082A5 - Ergopeptin derivatives, their preparation and use - Google Patents
Ergopeptin derivatives, their preparation and use Download PDFInfo
- Publication number
- CH642082A5 CH642082A5 CH547679A CH547679A CH642082A5 CH 642082 A5 CH642082 A5 CH 642082A5 CH 547679 A CH547679 A CH 547679A CH 547679 A CH547679 A CH 547679A CH 642082 A5 CH642082 A5 CH 642082A5
- Authority
- CH
- Switzerland
- Prior art keywords
- hydrogen
- formula
- compounds
- carbon atoms
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 239000001257 hydrogen Substances 0.000 claims abstract description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 4
- 238000009833 condensation Methods 0.000 abstract description 3
- 230000005494 condensation Effects 0.000 abstract description 3
- 102000003946 Prolactin Human genes 0.000 abstract description 2
- 108010057464 Prolactin Proteins 0.000 abstract description 2
- 229960003638 dopamine Drugs 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 229940097325 prolactin Drugs 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical class C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- ZCQPDHIMSLIIDW-MEBBXXQBSA-N (6ar,9r)-5,7-dimethyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxylic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=C(C)NC3=C1 ZCQPDHIMSLIIDW-MEBBXXQBSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229950001817 alpha-ergocryptine Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- TUNQTZDLMCRIIZ-UHFFFAOYSA-N pyrrolo[1,2-a]pyrazine hydrochloride Chemical compound Cl.C1=NC=CN2C=CC=C21 TUNQTZDLMCRIIZ-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (39)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH547679A CH642082A5 (en) | 1979-06-12 | 1979-06-12 | Ergopeptin derivatives, their preparation and use |
| DE19803020895 DE3020895A1 (de) | 1979-06-12 | 1980-06-02 | Ergopeptinderivate, verfahren zu deren herstellung sowie diese ergopeptinderivate enthaltende pharmazeutischen zusammensetzungen |
| FI801810A FI70222C (fi) | 1979-06-12 | 1980-06-05 | Foerfarande foer framstaellning av terapeutiskt anvaendbara eropeptinderivat |
| NL8003318A NL8003318A (nl) | 1979-06-12 | 1980-06-06 | Ergopeptinederivaten en werkwijze voor het bereiden van deze derivaten en van geneesmiddelen die deze deriva- ten bevatten. |
| CY1331A CY1331A (en) | 1979-06-12 | 1980-06-09 | Ergot peptide derivatives |
| GB8018827A GB2053908B (en) | 1979-06-12 | 1980-06-09 | Ergot peptide derivatives |
| MA19070A MA18872A1 (fr) | 1979-06-12 | 1980-06-09 | Nouveaux alcaloides de l'ergot de seigle,leur preparation et leur application comme medicaments |
| BE1/9842A BE883711A (fr) | 1979-06-12 | 1980-06-09 | Nouveaux alcaloides peptidiques de l'ergot de seigle, leur preparation et leur application comme medicaments |
| IT48924/80A IT1146938B (it) | 1979-06-12 | 1980-06-10 | Alcaloidi peptidici della segale cornuta,loro preparazione e loro applicazione come medicamenti |
| IL60287A IL60287A (en) | 1979-06-12 | 1980-06-10 | 2-methyl-ergot peptide derivatives,their preparation and pharmaceutical compositions containing them |
| CA000353712A CA1169856A (en) | 1979-06-12 | 1980-06-10 | Ergot peptide derivatives, their preparation and pharmaceutical compositions containing them |
| SE8004306A SE445645B (sv) | 1979-06-12 | 1980-06-10 | Ergopeptinderivat, forfarande for framstellning och farmaceutiska beredningar derav |
| NO80801724A NO154635C (no) | 1979-06-12 | 1980-06-10 | Fremgangsmaate for fremstilling av terapeutisk aktive ergotalkaloider. |
| DK250580A DK250580A (da) | 1979-06-12 | 1980-06-10 | Fremgangsmaade til fremstilling af ergopeptinderivater |
| NZ193992A NZ193992A (en) | 1979-06-12 | 1980-06-10 | 2-methyl-8(r or s)-ergot peptide alkaloids |
| HU801473A HU184299B (en) | 1979-06-12 | 1980-06-11 | Process for producing ergopeptine derivatives |
| CS945281A CS221925B2 (cs) | 1979-06-12 | 1980-06-11 | Způsob výroby ergopeptinových derivátů |
| CS413180A CS221924B2 (cs) | 1979-06-12 | 1980-06-11 | Způsob výroby ergopeptinových derivátů |
| IE1206/80A IE49610B1 (en) | 1979-06-12 | 1980-06-11 | Ergot peptide derivatives,their preparation and pharmaceutical compositions containing them |
| ES492332A ES8105331A1 (es) | 1979-06-12 | 1980-06-11 | Procedimiento para preparar un alcaloide 2-metil-8(r) o (s) ergotpeptido |
| FR8012931A FR2458552A1 (fr) | 1979-06-12 | 1980-06-11 | Nouveaux alcaloides peptidiques de l'ergot de seigle, leur preparation et leur application comme medicaments |
| AU59233/80A AU545645B2 (en) | 1979-06-12 | 1980-06-11 | Ergot alkaloid |
| SU802937551A SU953984A3 (ru) | 1979-06-12 | 1980-06-11 | Способ получени производных эргопептина или их солей |
| PT71374A PT71374B (en) | 1979-06-12 | 1980-06-11 | Process for the preparation of ergotic peptide derivates having pharmacological properties |
| AT0306580A AT378534B (de) | 1979-06-12 | 1980-06-11 | Verfahren zur herstellung von neuen ergopeptinderivaten |
| KR8002298A KR840000573B1 (en) | 1979-06-12 | 1980-06-11 | Process for preparing ergot peptide derivatives |
| IE1388/85A IE49611B1 (en) | 1979-06-12 | 1980-06-11 | A 2-methyl ergot peptide alkaloid |
| JP7957580A JPS562992A (en) | 1979-06-12 | 1980-06-11 | Ergot peptide derivative* its manufacture and drug composition containing it |
| ZA00803516A ZA803516B (en) | 1979-06-12 | 1980-06-12 | Ergot peptide derivatives,their preparation and pharmaceutical compositions containing them |
| AR281379A AR231142A1 (es) | 1979-06-12 | 1980-06-12 | Procedimiento para preparar 2-metil-8(r)o(s)ergopeptidos |
| ES498871A ES8205194A1 (es) | 1979-06-12 | 1981-01-28 | Procedimiento para preparar un alcaloide 2-metil-8(r) o (s) ergotpeptido |
| ES498872A ES8205195A1 (es) | 1979-06-12 | 1981-01-28 | Procedimiento para preparar un alcaloide 2-metil-8(r) o (s) ergotpeptido |
| PH27511A PH19334A (en) | 1979-06-12 | 1982-06-29 | Ergot peptide derivatives and pharmaceutical compositions containing them |
| GB08236817A GB2121030B (en) | 1979-06-12 | 1982-12-24 | Ergot peptide derivatives |
| US06/493,335 US4547500A (en) | 1979-06-12 | 1983-05-10 | Ergot peptide derivatives, their preparation and pharmaceutical compositions containing them |
| KR1019840000378A KR840000574B1 (ko) | 1979-06-12 | 1984-01-27 | 엘고트 펩타이드 유도체의 제조방법 |
| SE8500490A SE457260B (sv) | 1979-06-12 | 1985-02-04 | Mellanprodukt foer framstaellning av 2-metyl-ergopeptiner och saett att framstaella mellanprodukten |
| KE3622A KE3622A (en) | 1979-06-12 | 1986-04-14 | Ergot peptide derivatives,their preparation and pharmaceutical compositions containing them |
| HK402/86A HK40286A (en) | 1979-06-12 | 1986-05-29 | Ergot peptide derivatives,their preparation and pharmaceutical compositions containing them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH547679A CH642082A5 (en) | 1979-06-12 | 1979-06-12 | Ergopeptin derivatives, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH642082A5 true CH642082A5 (en) | 1984-03-30 |
Family
ID=4294236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH547679A CH642082A5 (en) | 1979-06-12 | 1979-06-12 | Ergopeptin derivatives, their preparation and use |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS562992A (enExample) |
| BE (1) | BE883711A (enExample) |
| CH (1) | CH642082A5 (enExample) |
| ZA (1) | ZA803516B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2838991A1 (en) * | 2011-06-23 | 2012-12-27 | Map Pharmaceuticals, Inc. | Novel fluoroergoline analogs |
-
1979
- 1979-06-12 CH CH547679A patent/CH642082A5/de not_active IP Right Cessation
-
1980
- 1980-06-09 BE BE1/9842A patent/BE883711A/fr not_active IP Right Cessation
- 1980-06-11 JP JP7957580A patent/JPS562992A/ja active Granted
- 1980-06-12 ZA ZA00803516A patent/ZA803516B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0147478B2 (enExample) | 1989-10-13 |
| JPS562992A (en) | 1981-01-13 |
| BE883711A (fr) | 1980-12-09 |
| ZA803516B (en) | 1982-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD206379A5 (de) | Verfahren zur herstellung von ergopeptinderivaten | |
| DE2824905A1 (de) | Neue 1, 2, 3, 4, 6, 7-hexahydro-11 balphah-benzo(a)chinolizin-derivate und verfahren zur herstellung derselben | |
| DE2851028A1 (de) | Neue indolo eckige klammer auf 2.3-a eckige klammer zu chinolizidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitung | |
| DE2523743A1 (de) | Verbindungen mit ergolinstruktur, solche enthaltende arzneimittel sowie verfahren zur herstellung derselben | |
| CH520680A (de) | Verfahren zur Herstellung neuer Mutterkornpeptidalkaloide | |
| DE2124640A1 (de) | Verfahren zur Herstellung von Dihydrolysergsäure, Dihydroisolysergsäure und Dihydrolysergsäure- und Dihydroisolysergsäurederivaten sowie Dihydrolysergsäure- und Dihydroisolysergsäurederivate und ihre Verwendung | |
| DE68905363T2 (de) | Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten. | |
| CH642082A5 (en) | Ergopeptin derivatives, their preparation and use | |
| CH524612A (de) | Verfahren zur Herstellung von neuen Imidazolderivaten | |
| DE1934392C3 (de) | Neue 2-Pyridylthioamide und Verfahren zu ihrer Herstellung | |
| DE2424540A1 (de) | Ergolincarbamate | |
| CH649998A5 (de) | Ergolinderivate, ein verfahren zu ihrer herstellung und heilmittel, enthaltend diese ergolinderivate als wirkstoff. | |
| DE3128676A1 (de) | Amidderivate der p-isobutylphenylpropionsaeure, ihre herstellung und diese enthaltende arzneimittel | |
| WO1983002775A1 (en) | Ergot alkaloids, manufacturing process thereof and pharmaceutical preparations containing them | |
| DE69905191T2 (de) | Kondensierte pyridazinonverbindungen | |
| DE2520131A1 (de) | Stickstoffhaltige polycyclische verbindungen und verfahren zu deren herstellung | |
| EP0026899A1 (de) | Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung | |
| CH643560A5 (en) | Ergopeptin derivatives, their preparation and use | |
| CH652720A5 (en) | Ergoline derivatives, their preparation and use | |
| DE3020895A1 (de) | Ergopeptinderivate, verfahren zu deren herstellung sowie diese ergopeptinderivate enthaltende pharmazeutischen zusammensetzungen | |
| AT392640B (de) | Verfahren zur herstellung von neuen 8alpha-acylaminoergolinen | |
| CH654838A5 (fr) | Ergolinderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen. | |
| DE3013346A1 (de) | Dibenz(de,g)isochinolin-derivate, verfahren zu deren herstellung, diese enthaltende arzneimittel sowie deren verwendung bei der bekaempfung von erkrankungen des zentralen nervensystems | |
| CH640235A5 (de) | 8-beta-hydrazinomethyl-ergolinderivate und verfahren zu ihrer herstellung. | |
| CH602766A5 (en) | 10-Alpha-methoxy-di:hydro-beta-ergosine derivs. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |